SCHEMBL6071502

SCHEMBL6071502

CN(C)C(=O)c1cc(N(C)c2cccnc2)cc2c(Nc3ccc(F)c(Cl)c3)c(C#N)cnc12

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAP3K8 P41279 12/20 0.64
EGFR P00533 11/20 0.53
MAPK14 Q16539 2/20 0.48
MAPK13 O15264 1/20 0.48
EIF2AK2 P19525 1/20 0.48
MAPK12 P53778 1/20 0.48
MAPK11 Q15759 1/20 0.48
SRC P12931 2/20 0.48
PRKACA P17612 2/20 0.48
PRKACG P22612 2/20 0.48
PRKACB P22694 2/20 0.48
IKBKB O14920 1/20 0.48
MMP3 P08254 1/20 0.48
CYP3A4 P08684 1/20 0.48
PRKCA P17252 1/20 0.48
MAPKAPK2 P49137 1/20 0.48
ERBB2 P04626 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6071770 0.90 MAP3K8 (0.50) MAP3K8EGFRERBB2
SCHEMBL6071650 0.90 MAP3K8 (0.61) MAP3K8EGFRMAPK14MAPK13EIF2AK2
SCHEMBL6071264 0.89 MAP3K8 (0.72) MAP3K8EGFRMAPK14SRCPRKACA
SCHEMBL6071729 0.88 MAP3K8 (0.61) MAP3K8EGFRCYP3A4MAPKAPK2ERBB2
SCHEMBL4960392 0.86 MAP3K8 (0.69) MAP3K8EGFRMAPK14SRCCYP3A4
SCHEMBL6071363 0.86 MAP3K8 (0.71) MAP3K8EGFRMAPK14MAPK13MAPK12
SCHEMBL6071588 0.85 MAP3K8 (0.62) MAP3K8EGFRMAPK14SRCPRKACA
SCHEMBL4960401 0.85 MAP3K8 (0.67) MAP3K8EGFRMAPK14MAPK13EIF2AK2
SCHEMBL6071505 0.84 MAP3K8 (0.77) MAP3K8EGFRMAPK14MAPK13EIF2AK2
SCHEMBL6071434 0.83 MAP3K8 (0.69) MAP3K8EGFRMAPK14SRCPRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same WYETH (US) 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same TNNI3K, CSNK1A1L, CDKL1 MAP3K8 84/4885EGFR 4122/4885MAPK14 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.